TIME Best Inventions honors extraordinary innovations changing lives , /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions. There are over 10 million people living with Parkinson's disease globally,and while there is currently no cure, Medtronic deep brain stimulatio ...

Core Insights - ONWARD Medical N.V. is recognized as a leading neurotechnology company focused on therapies to restore movement and function in individuals with spinal cord injuries and other movement disabilities [1][3] - BNP Paribas' broker Portzamparc has initiated coverage of ONWARD Medical with a Buy rating and a target price of EUR 10.20, indicating strong analyst confidence in the company's growth prospects [1][2] Company Developments - The ARC-EX System has received clearance for commercial use in both the U.S. and Europe, marking a significant transition for ONWARD into a commercial-stage company [2][3] - The company is preparing to initiate a global pivotal study for its investigational implantable ARC-IM platform, which aims to address unmet needs such as blood pressure instability following spinal cord injury [2][3] Market Position - The initiation report from Portzamparc expands ONWARD's equity research coverage to five leading banks, all maintaining a Buy rating and target prices significantly above current trading levels [2] - ONWARD Medical has been awarded 10 Breakthrough Device designations from the FDA, highlighting its innovative approach and regulatory recognition [3] Product Information - The ARC-EX System is designed to deliver programmed, transcutaneous electrical spinal cord stimulation to improve hand sensation and strength in individuals aged 18 to 75 with chronic, non-progressive neurological deficits due to incomplete spinal cord injuries [8] - Other investigational products, including ARC-IM and ARC-BCI, are currently not available for commercial use [9] Company Structure - ONWARD Medical is headquartered in the Netherlands, with additional facilities in Switzerland and a U.S. office in Boston, Massachusetts [4] - The company is publicly listed on Euronext Paris, Brussels, and Amsterdam, with its U.S. ADRs traded on OTCQX [4]

Core Insights - ONWARD Medical N.V. is a leading neurotechnology company focused on therapies for spinal cord injuries and movement disabilities, with a recent Buy rating initiated by BNP Paribas' broker Portzamparc and a target price of EUR 10.20 [1][2] Company Overview - ONWARD Medical is pioneering therapies to restore movement and independence in individuals with spinal cord injuries, having developed ARC Therapy and received 10 Breakthrough Device designations from the FDA [3] - The ARC-EX® System is now cleared for commercial sale in both the U.S. and Europe, marking a significant transition to a commercial-stage company [2][3] - The company is also advancing the investigational ARC-IM® platform, which aims to address unmet needs such as blood pressure instability post-injury and can integrate with brain-computer interfaces and AI for thought-driven movement [3] Market Position - The initiation of coverage by Portzamparc expands ONWARD's equity research coverage to five banks, all maintaining a Buy rating and target prices significantly above current trading levels, indicating strong analyst confidence in the company's growth prospects [2]

Core Insights - ONWARD Medical N.V. has successfully implanted its investigational ARC-BCI Therapy in two additional individuals with spinal cord injury, bringing the total to five successful implants, reinforcing its leadership in BCI-enabled movement solutions [1][2][4] Group 1: Company Achievements - The latest procedures were performed at Centre Hospitalier Universitaire Vaudois in Switzerland, showcasing the company's collaboration with leading medical professionals [2] - The fourth procedure involved a 48-year-old man with a spinal cord injury from 2024, while the fifth was on a 37-year-old woman with an injury from 2011, indicating the therapy's application across different injury timelines [3] - The CEO of ONWARD Medical emphasized the importance of these procedures in advancing understanding of the therapy and moving closer to enabling thought-driven movement for individuals with paralysis [4] Group 2: Technology and Research - The ARC-BCI System combines brain-computer interface technology with spinal cord stimulation to create a wireless connection that allows thought-driven movement after paralysis, utilizing AI to decode brain signals [4] - The therapy is part of ongoing clinical feasibility studies supported by grants from the European Innovation Council and the Christopher & Dana Reeve Foundation, indicating strong institutional backing [5] - The therapy has been recognized with Breakthrough Device Designation by the FDA, highlighting its potential impact in the medical field [4] Group 3: Media and Public Engagement - ONWARD ARC-BCI Therapy was featured on CBS 60 Minutes, enhancing public awareness and interest in the therapy and its potential benefits for individuals with spinal cord injuries [6][8]